<DOC>
	<DOC>NCT01692886</DOC>
	<brief_summary>This study is primarily designed to evaluate the IgG immune responses to the 13 pneumococcal serotypes induced by 13vPnC compared with the immune responses induced by 7vPnC when measured 1 month after the infant series, and to evaluate the acceptability of the safety profile of 13vPnC as measured by the incidence rates of local reactions, systemic events and adverse events.</brief_summary>
	<brief_title>A Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) In Healthy Infants In China</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1. Aged 42 to 77 days (approximately 2 months) at the time of enrollment. 2. Healthy infant as determined by medical history, physical examination, and judgment of the investigator. 1. Previous vaccination with licensed or investigational pneumococcal vaccine. 2. A previous anaphylactic reaction to any vaccine or vaccinerelated component. 3. Contraindication to vaccination with pneumococcal vaccines.</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>77 Days</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>13vPnC</keyword>
	<keyword>7vPnC</keyword>
	<keyword>Healthy subjects</keyword>
	<keyword>China</keyword>
</DOC>